Loading
A phase 1/2 trial of donor-derived NK cell infusion in non-small-cell lung cancer, run by Precision Biotech Taiwan Corp., now recruiting.
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients is a phase 1/2 interventional study registered as NCT04616209 by Precision Biotech Taiwan Corp., with 24 participants planned, started 2020-11-15 and due to reach its primary completion in 2027-12-30. Interventions recorded: donor-derived NK cell infusion.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/